ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
ESMO 2023: A new immunotherapy, volrustomig, for the first-line treatment of advanced kidney cancer
Blocking the action of two proteins in cancer cells (PD-1 [...]
ESMO 2023: A new first-line treatment, toripalimab, for advanced kidney cancer
Advanced/metastatic kidney cancer is often treated with a combination of [...]
ESMO 2023: Belzutifan for the treatment of advanced kidney cancer
Treatments for people with metastatic kidney cancer have changed over [...]
Patients with metastatic kidney cancer on immunotherapy may benefit from nephrectomy
Surgery to remove the kidney and tumour (nephrectomy) has an [...]
Injectable form of nivolumab
An injectable form of nivolumab has been successful in clinical [...]
SMC approves belzutifan for VHL kidney cancer in Scotland
We are delighted to announce that the Scottish Medicines Consortium [...]
Pembrolizumab plus lenvatinib for non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment for people with [...]
Belzutifan significantly delays progression of advanced kidney cancer after other treatments have failed
Kidney cancers often have mutations in a gene called the von Hippel-Lindau [...]
Corticosteroids during treatment with nivolumab may not affect survival in kidney cancer
A recent study published in the journal JAMA Oncology has [...]
